TP53 and cancer: Based on these findings, both NB cell populations were treated with PRIMA-1MET, an activator of the mutant P53 protein [11,12,13,14] that has been found to facilitate apoptosis induction in cancer cells [57], and with PTC596, a BMI-1 inhibitor currently undergoing clinical trials [38,58].